Inhibition of aberrant proliferation and induction of apoptosis in HER-2/neu oncogene transformed human mammary epithelial cells by N-(4-hydroxyphenyl)retinamide

被引:36
|
作者
Jinno, H
Steiner, MG
Mehta, RG
Osborne, MP
Telang, NT
机构
[1] Rockefeller Univ, Div Carcinogenesis & Prevent, Strang Canc Res Lab, New York, NY 10021 USA
[2] Cornell Univ, Coll Med, Dept Otolaryngol, New York, NY USA
[3] Cornell Univ, Coll Med, Dept Surg, New York, NY USA
[4] Univ Illinois, Coll Med, Dept Surg Oncol, Chicago, IL USA
关键词
D O I
10.1093/carcin/20.2.229
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Epithelial cells from non-cancerous mammary tissue in response to exposure to chemical carcinogens or transfection with oncogenes exhibit hyperproliferation and hyperplasia prior to the development of cancer. Aberrant proliferation may, therefore, represent a modifiable early occurring preneoplastic event that is susceptible to chemoprevention of carcinogenesis. The synthetic retinoid N-(4-hydroxyphenyl)retinamide (HPR), has exhibited preventive efficacy in several in vitro and in vivo breast cancer models, and represents a promising chemopreventive compound for clinical trials. Clinically relevant biochemical and cellular mechanisms responsible for the chemopreventive effects of HPR, however, are not fully understood. Experiments were performed on preneoplastic human mammary epithelial 184-B5/HER cells derived from reduction mammoplasty and initiated for tumorigenic transformation by overexpression of HER-2/neu oncogene, to examine whether HPR inhibits aberrant proliferation of these cells and to identify the possible mechanism(s) responsible for the inhibitory effects of HPR, Continuous 7-day treatment with HPR produced a dose-dependent, reversible growth inhibition, Long-term (21 day) treatment of 184-B5/HER cells with HPR inhibited anchorage-dependent colony formation by similar to 80% (P < 0.01) relative to that observed in the solvent control, A 24 h treatment with cytostatic 400 nM HPR produced a 25% increase (P = 0.01) in G(0)/G(1) phase, and a 36% decrease (P = 0.01) in S phase of the cell cycle. HPR treatment also induced a 10-fold increase (P = 0.02) in the sub-Go (apoptotic) peak that was down-regulated in the presence of the antioxidant N-acetyl-L-cysteine, Treatment with HPR resulted in a 30% reduction of cellular immunoreactivity to tyrosine kinase, whereas immunoreactivity to p185(HER) remained essentially unaltered. HPR exposure resulted in time-dependent increase in cellular metabolism of the retinoid as evidenced by increased formation of the inert metabolite N-(4-methoxyphenyl) retinamide (MPR) and progressive increase in apoptosis, Thus, HPR-induced inhibition of aberrant proliferation may be caused, in part, by its ability to inhibit HER-2/neu-mediated proliferative signal transduction, retard cell cycle progression and upregulate cellular apoptosis.
引用
收藏
页码:229 / 236
页数:8
相关论文
共 50 条
  • [21] Increase of ceramide and induction of mixed apoptosis necrosis by N-(4-hydroxyphenyl)-retinamide in neuroblastoma cell lines
    Maurer, BJ
    Metelitsa, LS
    Seeger, RC
    Cabot, MC
    Reynolds, CP
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (13): : 1138 - 1146
  • [22] COX-2 is essential for HER2/neu to suppress N(4-hydroxyphenyl)retinamide (4-HPR) apoptosis in breast cancer cells.
    Tari, A
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2003, 12 (11) : 1343S - 1344S
  • [23] Is growth inhibition and induction of apoptosis in lung cancer cell lines by fenretinide [N-(4-hydroxyphenyl)retinamide] sufficient for cancer therapy?
    Ohlmann, CH
    Jung, C
    Jaques, G
    INTERNATIONAL JOURNAL OF CANCER, 2002, 100 (05) : 520 - 526
  • [24] Mitochondrial bioenergetics is an apoptogenic regulator for N-(4-hydroxyphenyl)retinamide in premalignant and malignant prostate epithelial cells
    Hail, Numsen
    Chen, Ping
    Kepa, Jadwiga
    CANCER RESEARCH, 2009, 69
  • [25] HER2/neu reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer cells by decreasing nitric oxide production
    Simeone, AM
    Broemeling, LD
    Rosenblum, J
    Tari, AM
    ONCOGENE, 2003, 22 (43) : 6739 - 6747
  • [26] Mitochondrial bioenergetics is an apoptogenic regulator for N-(4-hydroxyphenyl)retinamide in premalignant and malignant prostate epithelial cells
    Hail, Numsen
    Chen, Ping
    Kepa, Jadwiga
    CANCER RESEARCH, 2009, 69
  • [27] HER2/neu reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer cells by decreasing nitric oxide production
    Ann-Marie Simeone
    Lyle David Broemeling
    Josh Rosenblum
    Ana Maria Tari
    Oncogene, 2003, 22 : 6739 - 6747
  • [28] N-(4-hydroxyphenyl)Retinamide Mediates Preservation of Retinal Ganglion Cells Through Induction of Ceramide Biosynthesis
    Narayan, S.
    Tsivkovskaia, N.
    Bui, T. V.
    Mata, N. L.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
  • [29] N-(4-hydroxyphenyl) retinamide is cytotoxic to melanoma cells in vitro through induction of programmed cell death
    Montaldo, PG
    Pagnan, G
    Pastorino, F
    Chiesa, V
    Raffaghello, L
    Kirchmeier, M
    Allen, TM
    Ponzoni, M
    INTERNATIONAL JOURNAL OF CANCER, 1999, 81 (02) : 262 - 267
  • [30] REGULATION OF APOPTOSIS INDUCED BY THE RETINOID N-(4-HYDROXYPHENYL) RETINAMIDE AND EFFECT OF DEREGULATED BCL-2
    DELIA, D
    AIELLO, A
    FORMELLI, F
    FONTANELLA, E
    COSTA, A
    MIYASHITA, T
    REED, JC
    PIEROTTI, MA
    BLOOD, 1995, 85 (02) : 359 - 367